Technology Transfer

Case Western Reserve University's Technology Transfer Office (TTO) serves our innovators with full-spectrum intellectual property services. For both faculty and students, we provide support for intellectual property and commercialization that spans the research & development continuum. We serve our researchers by assessing and building upon the commercial potential of new ideas and inventions.

Through interaction with our inventors, regional and national networks, including our affiliate healthcare systems, and potential commercial partners, we endeavor to determine the best path of translation and ultimate commercialization for University intellectual assets.

Consistent with the University's mission, the Technology Transfer Office is working towards enhancing its role in the promotion of an inclusive culture of global citizenship by exploring issues of access to essential medicines by resource-limited countries. This work includes moving towards the Universities Allied for Essential Medicine's Global Access Licensing Framework.

Recent News

NervGen Presents Interim Phase 1 Clinical Trial Data for NVG-291 at the American Neurological Association 14th Annual Meeting
--NervGen, October 18, 2021

Lucid Diagnostics Announces Pricing of Initial Public Offering
--PAVmed, October 13, 2021

Peak Nanosystems raises $25 million from Squadron Capital
--Crain's Cleveland Business, October 11, 2021

NervGen Pharma Partners with Imeka to Use Novel Neuroimaging Technology in Clinical Trails
--NervGen Pharma, September 27th 2021

Lucid Diagnostics, a medtech company with ties to Case Western Reserve University, plans to go public
--Crain's Cleveland, September 27, 2021

Please visit our TTO News webpage for more articles and press releases about TTO success stories.

For Questions About...

  • Your Invention Disclosure Form (IDF), please contact Joy Chen at 216.368.0362.
  • A Material Transfer Agreement (MTA) please contact Walid Jalabi at 216.368.2151.
  • A Data Use Agreement (DUA), please contact
  • Anything else, please contact Daniel Pendergast at 216.368.0184.